Morris J Brown

List of Publications by Year
in descending order

78 papers	10,748 citations	109321 35 h-index	69250 77 g-index
81 all docs	81 docs citations	81 times ranked	18044 citing authors

#	Article	IF	Citations
1	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	21.4	1,818
2	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	27.8	1,328
3	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics, 2018, 50, 1412-1425.	21.4	924
4	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet, The, 2015, 386, 2059-2068.	13.7	904
5	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nature Genetics, 2017, 49, 403-415.	21.4	492
6	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
7	Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nature Genetics, 2013, 45, 1055-1060.	21.4	446
8	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	27.8	353
9	Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet, The, 1999, 353, 2008-2013.	13.7	323
10	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	21.4	281
11	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	21.4	261
12	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes and Endocrinology,the, 2018, 6, 464-475.	11.4	206
13	Evaluation of the Sensitivity and Specificity of¹¹C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 100-109.	3.6	203
14	A 5â€hydroxytryptamine receptor in human atrium. British Journal of Pharmacology, 1990, 100, 879-885.	5.4	178
15	Microarray, qPCR, and<i>KCNJ5</i>Sequencing of Aldosterone-Producing Adenomas Reveal Differences in Genotype and Phenotype between Zona Glomerulosa- and Zona Fasciculata-Like Tumors. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E819-E829.	3.6	164
16	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. American Journal of Human Genetics, 2014, 94, 349-360.	6.2	158
17	Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet, The, 2011, 377, 312-320.	13.7	149
18	Association of the G s Î± Gene With Essential Hypertension and Response to Î²-Blockade. Hypertension, 1999, 34, 8-14.	2.7	136

#	Article	IF	Citations
19	Pregnancy, Primary Aldosteronism, and AdrenalCTNNB1Mutations. New England Journal of Medicine, 2015, 373, 1429-1436.	27.0	123
20	Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. Hypertension, 2017, 70, .	2.7	123
21	Multi-ancestry genome-wide geneâ€“smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nature Genetics, 2019, 51, 636-648.	21.4	112
22	Hypertension and ethnic group. BMJ: British Medical Journal, 2006, 332, 833-836.	2.3	107
23	Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clinical Science, 2004, 107, 167-173.	4.3	106
24	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 136-147.	11.4	99
25	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. PLoS ONE, 2018, 13, e0198166.	2.5	94
26	A Genome-Wide Search For Susceptibility Loci to Human Essential Hypertension. Hypertension, 2000, 35, 1291-1296.	2.7	84
27	Renin: friend or foe?. Heart, 2007, 93, 1026-1033.	2.9	74
28	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Doubleâ€Blind Randomized Controlled Trial. Journal of the American Heart Association, 2017, 6, .	3.7	74
29	Blood Pressure and the M235T Polymorphism of the Angiotensinogen Gene. Hypertension, 1996, 28, 907-911.	2.7	64
30	Novel Mechanism for Buffering Dietary Salt in Humans. Hypertension, 2017, 70, 930-937.	2.7	58
31	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 1147-1149.	27.0	56
32	Binding Sites for 125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography. Clinical Science, 1989, 77, 129-131.	4.3	50
33	Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension, 2017, 69, 189-196.	2.7	48
34	Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man. Clinical Science, 1988, 74, 359-363.	4.3	37
35	Pathoaetiology, Epidemiology and Diagnosis of Hypertension. Drugs, 2000, 59, 1-12.	10.9	37
36	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nature Genetics, 2021, 53, 1360-1372.	21.4	37

#	Article	IF	Citations
37	Success and failure of vaccines against reninâ€“angiotensin system components. Nature Reviews Cardiology, 2009, 6, 639-647.	13.7	33
38	Transcriptome Pathway Analysis of Pathological and Physiological Aldosterone-Producing Human Tissues. Hypertension, 2016, 68, 1424-1431.	2.7	33
39	The causes of essential hypertension. British Journal of Clinical Pharmacology, 1996, 42, 21-27.	2.4	32
40	Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?. Trials, 2015, 16, 80.	1.6	32
41	LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E836-E844.	3.6	32
42	Regulation of aldosterone secretion by Cav1.3. Scientific Reports, 2016, 6, 24697.	3.3	30
43	A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig in vitro. British Journal of Pharmacology, 1987, 91, 687-691.	5.4	27
44	DACH1 , a Zona Glomerulosa Selective Gene in the Human Adrenal, Activates Transforming Growth Factor-Î² Signaling and Suppresses Aldosterone Secretion. Hypertension, 2015, 65, 1103-1110.	2.7	24
45	Navigating the shoals in hypertension: discovery and guidance. BMJ, The, 2012, 344, d8218-d8218.	6.0	23
46	Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations. New England Journal of Medicine, 2016, 374, 1492-1494.	27.0	19
47	Development of [¹⁸F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. Journal of Medicinal Chemistry, 2021, 64, 9321-9329.	6.4	19
48	Chronotherapy in hypertension: the devil is in the details. European Heart Journal, 2020, 41, 1606-1607.	2.2	18
49	NEFM (Neurofilament Medium) Polypeptide, a Marker for Zona Glomerulosa Cells in Human Adrenal, Inhibits D1R (Dopamine D1 Receptor)â€“Mediated Secretion of Aldosterone. Hypertension, 2017, 70, 357-364.	2.7	17
50	Heterogeneity of Blood Pressure Response to Therapy. American Journal of Hypertension, 2010, 23, 926-928.	2.0	15
51	ANO4 (Anoctamin 4) Is a Novel Marker of Zona Glomerulosa That Regulates Stimulated Aldosterone Secretion. Hypertension, 2019, 74, 1152-1159.	2.7	15
52	Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. British Journal of Clinical Pharmacology, 2008, 65, 646-652.	2.4	14
53	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open, 2015, 5, e008951.	1.9	13
54	Resistant hypertension: resistance to treatment or resistance to taking treatment?. Heart, 2014, 100, 821-822.	2.9	12

#	Article	IF	Citations
55	Role of ANO4 in regulation of aldosterone secretion in the zona glomerulosa of the human adrenal gland. Lancet, The, 2015, 385, S62.	13.7	12
56	Therapeutic Potential of Vaccines in the Management of Hypertension. Drugs, 2008, 68, 2557-2560.	10.9	10
57	Ins and Outs of Aldosterone-Producing Adenomas of the Adrenal. Hypertension, 2014, 63, 24-26.	2.7	10
58	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: FigureÂ1. BMJ Open, 2015, 5, e007645.	1.9	10
59	Differences in Transcription and Translation of Long and Short GSÎ±, the Stimulatory G-Protein, in Human Atrium. Clinical Science, 1995, 89, 487-495.	4.3	9
60	A RATIONAL BASIS FOR SELECTION AMONG DRUGS OF THE SAME CLASS. British Heart Journal, 2003, 89, 687-694.	2.1	9
61	Selective Î²1 -adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium. British Journal of Pharmacology, 1999, 128, 135-141.	5.4	8
62	Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism. Lancet Diabetes and Endocrinology,the, 2016, 4, 805-807.	11.4	8
63	Expression of the Î±- and Î²-Subunits of the Stimulatory and Inhibitory G-Proteins in Î²1-Adrenoceptor-Blocked and non-Î²-Adrenoceptor-Blocked Human Atrium. Clinical Science, 1995, 88, 571-580.	4.3	7
64	The choice of diuretic in hypertension: saving the baby from the bathwater. Heart, 2011, 97, 1547-1551.	2.9	7
65	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. BMJ Open, 2015, 5, e008086.	1.9	7
66	Telling Tails. Hypertension, 2016, 68, 11-16.	2.7	6
67	AT2 Receptor Stimulation May Halt Progression of Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 436-443.	3.8	5
68	Clinical Value of Plasma Renin Estimation in the Management of Hypertension. American Journal of Hypertension, 2014, 27, 1013-1016.	2.0	5
69	Primary Aldosteronism: the spectre of cure. Clinical Endocrinology, 2015, 82, 785-788.	2.4	4
70	Investigation of primary aldosteronism in patients with resistant hypertension â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 600-601.	11.4	4
71	Rapid Diagnosis of Primary Aldosteronism. Hypertension, 2017, 70, 247-249.	2.7	3
72	Primary aldosteronism as a public health issue â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2016, 4, 973-974.	11.4	2

#	Article	IF	Citations
73	CONNed in Pregnancy. Hypertension, 2021, 78, 241-249.	2.7	2
74	Adrenaline and Alpha₂â€Adrenoceptors in Hypertension. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 16-20.	0.0	1
75	Response to Letter Regarding Article, â€œThe Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratioâ€. Circulation, 2008, 117, .	1.6	1
76	Platt versus Pickering: what molecular insight to primary hyperaldosteronism tells us about hypertension. JRSM Cardiovascular Disease, 2012, 1, 1-8.	0.7	1
77	Who Manages Hypertensive Patients? The Primary Care-Hospital Interface1. American Journal of Hypertension, 1998, 11, 740-743.	2.0	0
78	CTNNB1-Mutant Aldosterone-Producing Adenomas With Somatic Mutations of GNA11/GNAQ Have Distinct Phenotype and Genotype. Journal of the Endocrine Society, 2021, 5, A65-A66.	0.2	0